HepCBC Hepatitis C Education & Prevention Society needs input from Canadians who are HCV+ and their caregivers, for its patient group submission to the Canadian Drug Review (CADTH). New drug being reviewed: simeprevir (similar to boceprevir and telaprevir, but only one pill per day and does not require special food intake). Deadline: midnight, Sept. 11, 2013. Give input at: hepcbc.ca/2013/08/urgent-re... . THANKS!